These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice. Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410 [TBL] [Abstract][Full Text] [Related]
44. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Burcelin R; Gourdy P Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208 [TBL] [Abstract][Full Text] [Related]
45. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons. Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968 [TBL] [Abstract][Full Text] [Related]
46. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Madsbad S Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989 [No Abstract] [Full Text] [Related]
47. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? Doggrell SA Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603 [TBL] [Abstract][Full Text] [Related]
48. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132 [TBL] [Abstract][Full Text] [Related]
49. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054 [TBL] [Abstract][Full Text] [Related]
50. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Ryan D; Acosta A Obesity (Silver Spring); 2015 Jun; 23(6):1119-29. PubMed ID: 25959380 [TBL] [Abstract][Full Text] [Related]
51. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Ottney A Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759 [TBL] [Abstract][Full Text] [Related]
52. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927 [TBL] [Abstract][Full Text] [Related]
53. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228 [TBL] [Abstract][Full Text] [Related]